K260938 is an FDA 510(k) clearance for the PATH BGC. Classified as Catheter, Percutaneous, Neurovasculature (product code QJP), Class II - Special Controls.
Submitted by Crossroads Neurovascular, Inc. (Lake Forest, US). The FDA issued a Cleared decision on April 15, 2026 after a review of 26 days - a notably fast clearance cycle.
This device falls under the Neurology FDA review panel, regulated under 21 CFR 870.1250 - the FDA neurology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.
Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.
View all Crossroads Neurovascular, Inc. devices